Infinitopes develops a precision immunomics platform that identifies highly-expressed tumor antigens and employs advanced vector delivery systems to enhance T cell immunity against cancer. By initiating vaccine treatment at early stages of the patient's journey, the company aims to improve patient outcomes and reduce the risk of metastases.
Funding
$27.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail to eliminate tumors completely, leading to recurrence and metastasis. Existing immunotherapies may not be effective for all patients due to limited T cell recognition of tumor-specific antigens and suboptimal immune responses.
Solution
Infinitopes is developing a precision immunomics platform to identify highly expressed and immunogenic tumor antigens. The company uses advanced vector delivery systems to enhance T cell immunity against these antigens, aiming to create personalized cancer vaccines. Their approach focuses on initiating treatment early in the patient's journey to improve outcomes and reduce the risk of metastasis. The Infinitopes Precision Immunomics™ pipeline combines laboratory, computation, and machine learning workflows to identify tumor antigens with high sensitivity.
Target Audience
The primary target audience includes cancer patients, particularly those in early stages of the disease, and clinicians specializing in oncology and immunotherapy.
Features
- Identification of highly-expressed and immunogenic tumor antigens using the Infinitopes Precision Immunomics™ pipeline
- Vector platform designed to induce robust and durable T cell immunity
- Preclinical validation demonstrating superior tumor protection compared to known antigens
- Focus on early-stage vaccine administration to maximize treatment efficacy
- Integration with conventional cancer care protocols
- Capabilities in bleeding-edge laboratory, computation, and ML workflows